Insulet Co. (NASDAQ:PODD) Shares Bought by Jennison Associates LLC

Jennison Associates LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 21.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,342 shares of the medical instruments supplier’s stock after buying an additional 28,375 shares during the period. Jennison Associates LLC owned approximately 0.23% of Insulet worth $41,338,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Algert Global LLC increased its stake in Insulet by 25.6% during the second quarter. Algert Global LLC now owns 2,254 shares of the medical instruments supplier’s stock worth $455,000 after acquiring an additional 460 shares during the last quarter. Creative Planning grew its holdings in shares of Insulet by 35.0% during the 2nd quarter. Creative Planning now owns 7,430 shares of the medical instruments supplier’s stock worth $1,499,000 after purchasing an additional 1,928 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of Insulet by 10.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock worth $202,000 after purchasing an additional 95 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Insulet in the 2nd quarter valued at about $830,000. Finally, Handelsbanken Fonder AB lifted its position in Insulet by 5.5% in the third quarter. Handelsbanken Fonder AB now owns 17,216 shares of the medical instruments supplier’s stock valued at $4,007,000 after buying an additional 900 shares during the last quarter.

Insulet Stock Down 0.2 %

Shares of NASDAQ PODD opened at $278.48 on Wednesday. The business has a 50-day moving average of $269.18 and a two-hundred day moving average of $239.68. The company has a market capitalization of $19.53 billion, a price-to-earnings ratio of 47.68, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $286.39. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same quarter in the previous year, the business earned $0.71 earnings per share. On average, analysts forecast that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their price target on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Citigroup boosted their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. BTIG Research boosted their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Barclays increased their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.